Materials and methods for delivering nucleic acids to cochlear and vestibular cells
Provided herein are materials and methods for efficiently delivering nucleic acids to cochlear and vestibular cells.
1. An adeno-associated virus (AAV) vector comprising an Anc80 capsid protein and one or more transgenes selected from the group consisting of TMC1, TMC2, MYO7A, USCH1C, CDH23, PCDH15, SANS, CIB2, USH2A, VLGR1, WHRN, CLRN1, PDZD7.
2. A method of delivering a transgene to at least 80% of inner hair cells (IHCs) and at least 80% of outer ear hair cells (OHCs) in a subject's inner ear to treat a hearing disorder, the method comprising:
administering the AAV vector of claim 1 to the inner ear in a subject.
3. The method of claim 2 , wherein the Anc80 capsid protein has the sequence shown in SEQ ID NO:1.
4. The method of claim 2 , wherein the Anc80 capsid protein has the sequence shown in SEQ ID NO:2.
5. The method of claim 2 , wherein the transgene is under control of a heterologous promoter sequence.
6. The method of claim 5 , wherein the heterologous promoter sequence is selected from the group consisting of a CMV promoter, a CBA promoter, a CASI promoter, a PGK promoter, a EF-1 promoter, an alpha9 nicotinic receptor promoter, a prestin promoter, a KCNQ4 promoter, a Myo7a promoter, a Myo6 promoter, a Gfi1 promoter, a Vglut3 promoter, and an Atoh1 promoter.
7. The method of claim 2 , wherein the administering step comprises injecting the Anc AAV through the round window.
8. The method of claim 2 , wherein the Anc AAV is administered during a cochleostomy or during a canalostomy.
9. The method of claim 2 , wherein the Anc AAV is administered to the middle ear and/or the round window via one or more drug delivery vehicles.
10. The method of claim 2 , wherein expression of the transgene results in regeneration of inner hair cells (IHCs), or outer hair cells (OHCs), and one or more of spiral ganglion neurons, stria vascularis, vestibular hair cells, and/or vestibular ganglion neurons, thereby restoring hearing or vestibular function.
11. The AAV vector of claim 1 , wherein the transgene comprises TMC1.
12. The AAV vector of claim 1 , wherein the Anc80 capsid protein comprises the amino acid sequence of SEQ ID NO:1.
13. The AAV vector of claim 1 , wherein the Anc80 capsid protein comprises the amino acid sequence of SEQ ID NO:2.
14. The AAV vector of claim 1 , wherein the transgene is under control of a heterologous promoter sequence.
15. The AAV vector of claim 14 , wherein the heterologous promoter sequence is selected from the group consisting of a CMV promoter, a CBA promoter, a CASI promoter, a PGK promoter, a EF-1 promoter, an alpha9 nicotinic receptor promoter, a prestin promoter, a KCNQ4 promoter, a Myo7a promoter, a Myo6 promoter, a Gfi1 promoter, a Vglut3 promoter, and an Atoh1 promoter.
16. The AAV vector of claim 1 , wherein the AAV vector comprises a nucleotide sequence selected from the group consisting of: SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, and SEQ ID NO:8.